Application
Absolute quantification of
Yervoy® or its biosimilars
Specific labelling
Arginine: 13C6,15N4, >99%
Lysine: 13C6,15N2, >99%
Description
Ipilimumab, a recombinant human monoclonal antibody (IgG1 kappa immunoglobin), is an antineoplastic agent developed by Bristol-Myers Squibb and Medarex for the treatment of unresectable or metastatic melanoma in adults. The average weight of Ipilimumab is 148kDa. The labelled Ipilimumab-like stable isotope labelled standard is suited for quantification of Ipilimumab in human serum samples.
The mAb-like technology is patented.
This product is for research use only and is not intended for diagnostic or therapeutic use.
10 µg: 650 € HT
For any other quantities, please contact us
Legal:
This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only. Information about licenses for other uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.
Custom clearance and freight insurance costs to be borne by the customer.
